News Hub | News Direct

Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1

Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals Co-Founder Frank O’Donnell joined Steve Darling from Proactive to share what the company believe is groundbreaking potential of their new drug designed to extend telomeres, which could reverse aging and age-related diseases. During a recent interview, O'Donnell elaborated on the drug’s potential, supported by extensive research in mice and successful trials in larger animals like a German shepherd. Drawing from his background in ophthalmology at Johns Hopkins, O'Donnell explained that the drug is developed to fight conditions such as macular degeneration by manipulating telomeres—protective caps on chromosomes that degrade over time. This innovative approach has shifted the company's focus from merely prolonging life to actively reversing signs of aging. O'Donnell also touched on the drug’s promising implications for veterinary medicine, particularly its potential benefits for older dogs suffering from osteoarthritis. Upcoming studies on dogs are planned to further prove the drug's effectiveness before moving to human clinical trials slated to begin in January 2025. Emphasizing the drug's transformative capabilities, O'Donnell spoke of its potential global impact by rejuvenating biological clocks and enhancing overall health. Currently, Telomir Pharmaceuticals is not seeking additional funding, opting instead to focus on advancing their research and commencing significant clinical trials. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

May 07, 2024 03:02 PM Eastern Daylight Time

Video

PainReform Advances Pain Relief Solution, PRF-110, in Phase 3 Trial to Combat Opioid Crisis

PainReform Ltd

PainReform CEO Ilan Hadar joined Steve Darling from Proactive to discuss the company at the forefront of addressing the opioid crisis in the United States, is developing PRF-110, an innovative post-operative pain treatment designed as an alternative to traditional opioids. PRF-110 is applied directly by surgeons during procedures, offering patients up to 72 hours of continuous pain relief, potentially eliminating the need for additional pain medications post-surgery. The company is currently advancing a Phase III study in Texas to evaluate the effectiveness and safety of PRF-110. The study, which began in October 2023, has already seen significant progress with more than 50% of the target 400 patients enrolled. Completion of patient enrollment is expected by mid-year, and the study results are anticipated in the third quarter of the same year. A successful outcome from this study could pave the way for another Phase III trial focusing on soft tissue applications, slated to start in early 2025, with results expected by 2026. Should the upcoming trials confirm PRF-110’s efficacy and safety, PainReform plans to submit a New Drug Application in 2026. The company recognizes the significant market potential for non-opioid post-operative pain treatments, an area currently underexplored, and is positioning PRF-110 as a key player in transforming pain management practices post-surgery. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

May 07, 2024 12:16 PM Eastern Daylight Time

Video

Medicus Pharma Plans Private Placement for Clinical Development Acceleration

Medicus Pharma

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to shared insights with Proactive regarding the company's strategic initiatives, particularly its plans for a private placement of 100% unsecured convertible notes due in 2025. This move signifies a pivotal step in advancing the company's clinical development programs for novel and disruptive therapeutic assets. The private placement commenced with the first closing on May 1, involving the issuance of approximately US$5,172,500 aggregate principal amount of notes. Additionally, Medicus Pharma retains the option to issue additional notes, with the potential to reach up to US$10 million aggregate principal amount post-completion. Bokhari emphasized the company's unwavering focus on accelerating clinical development programs, underscoring the significance of the proceeds from the private placement. These funds will be allocated towards research and development initiatives, as well as fulfilling working capital needs crucial for advancing Medicus Pharma's therapeutic pipeline. One of the notable endeavors within the company's portfolio is SkinJect, a pioneering non-invasive treatment for basal cell skin cancer. Leveraging patented dissolvable microneedle patch technology, SkinJect aims to deliver chemotherapeutic agents effectively to eradicate tumor cells. By commercializing this innovative solution, Medicus Pharma seeks to address critical unmet medical needs and enhance patient outcomes in the realm of dermatological oncology. Through strategic financing and focused allocation of resources, Medicus Pharma is poised to bolster its clinical development efforts, bringing transformative therapeutic solutions to the forefront of patient care and medical innovation. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 07, 2024 12:06 PM Eastern Daylight Time

Video

Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program

Skye Bioscience Inc

Skye Bioscience CEO Punit Dhillon joined Steve Darling from Proactive to share news announcing the company's uplisting of its common stock to the Nasdaq stock exchange, trading under the ticker symbol "SKYE." This achievement signifies a significant milestone for the company, reflecting advancements in its Phase 2 clinical programs, financial position, and shareholder base. Dhillon further disclosed that Skye Bioscience reached another critical milestone by successfully dosing 56 patients with SBI-100 Ophthalmic Emulsion in its Phase 2a study and completing final study visits for all participants. SBI-100 OE, a cannabinoid receptor type 1 agonist administered topically to the eye, is designed to address the unmet needs of patients with elevated intraocular pressure related to primary open-angle glaucoma or ocular hypertension. Notably, all treated patients completed the study without early discontinuations due to adverse events, demonstrating the safety profile of SBI-100 OE. The company anticipates releasing topline data for the entire study in the second quarter, marking a significant milestone in advancing its clinical program. Skye Bioscience's move to the Nasdaq exchange underscores its commitment to enhancing visibility, expanding its investor base, and unlocking value for shareholders as it progresses in its mission to develop innovative therapies for ocular diseases. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

May 07, 2024 11:59 AM Eastern Daylight Time

Video

Shedding Light on Cystic Fibrosis Awareness Month

YourUpdateTV

Cystic fibrosis (CF) is a rare, progressive, and genetic disease that currently affects about 40,000 people in the United States. CF is the result of a defective gene, inherited from each parent, and the disease can impact people of all races and ethnicities. Recently, KC White, Board Chair of the Cystic Fibrosis Foundation, participated in a nationwide satellite media tour to discuss the disease, her personal journey, and how the Foundation is helping progress care and treatment options. A video accompanying this announcement is available at: https://youtu.be/8wj8u0JEqLU CF is a life-shortening disease that prevents our bodies from clearing mucus. This can lead to lung infections, poor nutrition, lung disease, and a host of unique challenges that can impact every aspect of a person’s life. When it was first discovered, it was considered a fatal pediatric disease. But due to transformative advancements in treatments and high-quality care, the life-expectancy for someone born with CF today is 56. While that number is climbing there is still a long way to go and unfortunately, not all people with CF equally benefit from this progress. KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood and is the first person with CF to serve as board chair. When she was diagnosed, she wasn’t expected to live past high school age, but her family refused to accept that fate, which prompted their dedication to the Foundation’s work. Because of recent treatments known as modulators, about 90% of the CF population (including KC) experienced an incredible transformation in their health. With this though, comes navigating unplanned challenges including careers, finances, family, and more. In addition to fueling the research, particularly in genetic therapies, that will lead to transformative treatments for the entire CF population, the CF Foundation works to support the CF community in all aspects of their lives through support programs and fostering connection opportunities. Every May, the cystic fibrosis community comes together for CF Awareness Month to educate the public about the rare disease, share personal stories, and encourage people to get involved and unite behind a shared mission: finding a cure for all people with CF. The CF Foundation is committed to finding a cure and providing all people with CF the opportunity to lead long, fulfilling lives. The Foundation is aggressively funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. For more information, visit CFF.ORG/CFMONTH About KC White KC White was elected chair of the Cystic Fibrosis Foundation’s Board of Trustees in 2022 after serving on the Board since 2005. Diagnosed with cystic fibrosis at age 3, White has been a committed volunteer and inspiring advocate for the Foundation since childhood, speaking at her first Foundation event when she was only 9 years old. She is the first person with CF to serve as board chair. White received her Master of Applied Positive Psychology from the University of Pennsylvania in 2022 and currently serves as an assistant instructor in the program. She is also the Head Varsity Women’s Lacrosse coach for the Chagrin Falls, Ohio, Tigers. She and her husband, Justin, have one son, Mac. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is a donor-supported nonprofit organization leading the relentless pursuit of a cure for cystic fibrosis. The Foundation is committed to providing all people with CF the opportunity to lead long, fulfilling lives by funding research and drug development, advancing high-quality, specialized care, and partnering with and advocating for the CF community. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. The organization supports and accredits a national network of over 130 CF care centers recognized by the National Institutes of Health as a model of care for a chronic disease. Also, the Foundation manages support programs and fosters connection opportunities for the CF community. Based in Bethesda, Md., the Foundation’s impact is made possible by the work of nearly 70 local chapters across the country. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 07, 2024 09:23 AM Eastern Daylight Time

Video

InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer's – New Studies Showcase INM-901's Therapeutic Abilities

Benzinga

By Meg Flippin, Benzinga Whether due to an aging population or overall population growth, cases of Alzheimer's are increasing. As it stands, nearly seven million Americans suffer from this disease that attacks memory and cognitive functions. By 2050, that’s forecast to reach close to 13 million people. The costs associated with treating Alzheimer's and dementia are projected to swell to $1 trillion by 2050 from $360 billion today. Alzheimer’s is the fifth leading cause of death for people 65 and older. There are several treatments on the market, but they focus on addressing the symptoms rather than repairing and regenerating the damaged neurons. Some drugs and treatments may slow the progression of cognitive decline, but none can reverse the effects of Alzheimer’s. That may change thanks to companies like InMed Pharmaceuticals Inc. (NASDAQ: INM). The leader in cannabinoid and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization has identified a rare cannabinoid to treat Alzheimer’s. Named INM-901 and based on early preclinical research, the cannabinoid analog showed potential to target several biological pathways associated with Alzheimer’s, providing neuroprotection to the brain neurons and improving neuronal function. Fighting Alzheimer’s With Cannabinoids Recent in vivo studies have shown that INM-901 can improve cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. Most recently, the company announced additional preclinical data demonstrating INM-901’s positive pharmacological effects. Several preclinical studies that were conducted in well-characterized Alzheimer’s models demonstrated that INM-901 was able to reduce neuroinflammation and improve neuronal function. The company said the studies also supported the observations made in previously released behavior studies in which locomotor activity, cognition and memory were improved. As a result of these studies, InMed said it plans to accelerate the development of its Alzheimer’s program. Currently, long-term behavioral and mechanism of action / receptor interaction studies are underway with data read-out expected in the third quarter. Meanwhile, InMed said the development of the chemistry, manufacturing and controls (CMC) for drug substance and oral drug product formulation are on-going. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed. “There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.” Multiple Mechanisms Of Action InMed said it is particularly encouraged that INM-901 has multiple potential ways of impacting the cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and the peroxisome proliferator-activated receptor (PPAR) signaling pathway. CB1 and CB2 receptors are part of the endocannabinoid system and are found throughout the body, including in the brain. CB1 receptors are primarily located in the central nervous system, particularly in areas involved in memory, cognition and motor function. CB2 receptors are involved in modulating neuroinflammation and immune responses. Activation of CB1 and CB2 receptors has been shown to help protect brain cells from damage and death. In Alzheimer’s where neuronal death is a hallmark feature, enhancing the activity of these receptors may help to slow down the progression of the disease, reports InMed. Activation of these receptors and other cellular receptors has also been shown to have an impact on neuroinflammation, which is believed to contribute to the progression of Alzheimer’s. As a result, InMed believes INM-901 could offer novel therapeutic strategies for the treatment of this devastating condition. Adding To Its Expertise To further develop INM-901, InMed is deepening its pedigree, and it recently added Dr. David G. Morgan, a renowned leader in neurodegenerative disease, to its Scientific Advisory Board. This reinforces InMed’s commitment to advancing its INM-901 program for the treatment of Alzheimer’s disease. Morgan is the director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat Alzheimer-related pathologies. “We are privileged to welcome someone of Dr. Morgan’s stature to our SAB, which underscores the recent progress we’ve achieved in the INM-901 program. Dr. Morgan’s significant contributions and pioneering breakthroughs have made him a leading authority in Alzheimer’s research. His guidance and expertise will be invaluable as we advance to the next stages of development of our INM-901 program in the treatment of Alzheimer’s,” said Hsu. The number of Alzheimer’s cases is set to soar in the years to come as the population ages. InMed wants to slow that, and is betting INM-901 can help. So far studies are backing that up, with more data to come this year. Featured photo by Natasha Connell on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 09:00 AM Eastern Daylight Time

Image

New Study Shows Cardio Diagnostics’ (NASDAQ: CDIO) PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has announced the publication of results from a budget impact modeling study for one of its leading clinical products. PrecisionCHD is an integrated genetic-epigenetic test for the detection of coronary heart disease (CHD). The peer-reviewed study, The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs, highlights the test’s promising developments. The study’s PrecisionCHD budget impact model was designed to evaluate the cost savings associated with using PrecisionCHD as the primary method of initial CHD assessment in place of current commonly used tests, including exercise electrocardiograms, coronary computed tomography angiography (CCTA) and angiograms. It considered factors such as the number of tests performed, the cost of each test and the impact of test results on treatment decisions. The results suggest that using PrecisionCHD could lead to significant cost savings for patients, with an estimated $113.6 million saved per year for a plan with one million members. These savings are primarily driven by the lower cost of PrecisionCHD compared to traditional tests, along with the reduced need for additional testing. Further, the model found that cost savings were not sensitive to patient demographics or insurance plan design. Similar results were observed for plans that exclude Medicare enrollees, only include Medicare enrollees (Part B or Medicare Advantage), offer large co-insurance rates and charge larger co-pays. PrecisionCHD is a multiomic DNA test that aids in the detection of stable CHD. The test evaluates six DNA methylation and ten genetic biomarkers and uses a proprietary machine learning model to interpret the genetically contextual methylation signals from these biomarkers. The sensitivity and specificity of this test are 79% and 76%, respectively, with the clinical validation study in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics being recently published in the Journal of American Heart Association. “The data from this study suggests that the broader use of PrecisionCHD as the initial test for detecting coronary heart disease can yield significant savings to payers,” said David Frisvold, PhD, Associate Professor in the Department of Economics at the University of Iowa and lead author of this study. “More importantly, the reported cost savings were shown to be generalizable to various health plans, potentially leading to increased access to care and improved outcomes for patients with CHD.” PrecisionCHD was recently awarded the Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code, 0449U, by the American Medical Association. It became effective on April 1, 2024. PrecisionCHD was also awarded the Innovation Technology contract from Vizient, the United States’ largest group purchasing organization, whose customer base encompasses over 60% of hospitals and 97% of academic medical centers in the country. Increasing Access, Reducing Costs Heart disease remains the leading cause of death among Americans. It is also one of the largest cost centers for payers. If the barriers to obtaining early cardiovascular care persist, the prevalence and costs associated with heart disease will likely increase. Currently, exercise electrocardiogram, CCTA and single photon emission computed tomography (SPECT) are among the initial tests used to diagnose CHD. These tests are resource-intensive, and require expensive infrastructure and specialized personnel, creating inherent barriers to broader adoption, especially in rural America. The continued reliance on these tests as the initial testing mode for CHD diagnosis could lead to higher costs for payers. Some of the current tests also involve risks that are associated with being exposed to radiation and contrast dyes that could affect the health of the patient long term. Cardio Diagnostics says that PrecisionCHD, on the other hand, is a more cost-efficient, highly scalable and less resource-intensive alternative for initial CHD detection testing. Its sensitive and specific performance minimizes the likelihood of false positives and negatives, potentially decreasing the need for costly follow-up tests and procedures. Furthermore, PrecisionCHD can be implemented virtually via telemedicine and at-home for blood sample collection. It can also be deployed in community settings via mobile health clinics as well as in a more traditional provider setting.This multimodal delivery approach means greater access for patients, and Cardio Diagnostics expects potential additional cost savings for payers as well, with earlier detection and management of CHD. “We believe that PrecisionCHD has the potential to revolutionize how coronary heart disease is diagnosed and managed,” said Robert Philibert, MD, PhD, Chief Medical Officer and co-founder of Cardio Diagnostics, and the senior author of the study. “We are confident that PrecisionCHD will drive value for many healthcare stakeholders including the patient, provider and payer.” Optimizing Cost Efficiency Health plans increasingly prioritize precision medicine solutions to enhance patient outcomes and optimize cost-efficiency, reflecting an industry-wide transition from personalized to precision medicine. This evolution is underpinned by integrating genomic, clinical and socio-economic data, enabling healthcare providers to customize treatment approaches and advance therapeutic innovation. Similarly, provider-led health plans face the same challenges in optimizing patient care while reducing unnecessary medical spending. PrecisionCHD stands out as a resource for health insurers and healthcare providers aiming to streamline the management and financial burden of CHD. As health systems increasingly adopt value-based care (VBC) models, the focus is increasingly on achieving superior patient outcomes and improved population health while maintaining cost-effectiveness. Throughout last year, the expansion and refinement of VBC models have underscored a concerted effort among healthcare providers, payers and policymakers to enhance patient care and manage expenses effectively. This strategic alignment with VBC frameworks highlights the significant role of tools like PrecisionCHD. These tools support targeted, data-driven decisions in CHD treatment and management, potentially revolutionizing approaches to healthcare delivery and cost management. Featured photo by Testalize.me on Unsplash Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

May 07, 2024 08:45 AM Eastern Daylight Time

Image

Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection

Benzinga

By James Blacker, Benzinga Despite the large numbers of people affected, cancer treatments have largely produced unsatisfactory results to curb the rise in cases. According to the American Cancer Society, more than 2 million new cancer cases are projected to be diagnosed in the United States in 2024, with over 600,000 cancer deaths expected to occur. Cancer is already the second-leading cause of death in the U.S. overall and the leading cause among people under 85, and analysis from Yale Medicine indicates that new cases of cancer are ticking upward. It’s clear the disease remains a formidable challenge, which is driving companies such as California-based biotechnology firm Renovaro Inc. (NASDAQ: RENB) to pioneer groundbreaking solutions to revolutionize diagnostics and offer more efficient treatment. Renovaro’s Mission To Advance Cancer Care Renovaro is on a mission to accelerate precision and offer personalized medicine for longevity. It leverages AI and biotechnology platforms to enable early diagnosis, better-targeted treatments and drug discovery. The company comprises a biotech arm, RenovaroBio, which focuses on advanced cell-gene immunotherapy, and an AI arm, RenovaroCube, which is committed to the early detection of cancer, its recurrence and subsequent treatment. Alliances With Industry Leaders What makes Renovaro’s approach so unique is its AI platform for diagnosis, which was made possible thanks to a strategic alliance with Nvidia Corp. (NASDAQ: NVDA). In August 2023 Renovaro announced its alliance with Nvidia’s Inception program, which allows it to deploy next-generation AI running on Nvidia’s latest chips for greater accuracy in cancer detection. Renovaro also announced in April that it plans to acquire 100% of Dutch health-tech firm Cyclomics, amending its initial agreement to acquire 75% of the company. Once the acquisition is complete, Renovaro will be able to use Cyclomics’ 4 th generation molecular technology, developed in partnership with Oxford Nanopore Technologies PLC (LON: ONT), to identify single cancer DNA molecules from a single vial of blood with nearly 100% accuracy. Introducing Flamingo: A Game-Changer In Multi-Cancer Detection Also in April this year, Renovaro unveiled Flamingo, “a potentially groundbreaking multi-cancer detection model,” according to the company. Flamingo leverages ultra-low pass whole genome sequencing of cell-free DNA (cfDNA), allowing early detection of cancers. While traditional cancer detection methods can fail to identify cancer at an early stage – when treatment is most effective – Flamingo harnesses the power of AI to perform highly accurate analysis of minute amounts of cfDNA data to distinguish cancer from healthy samples. Ultimately, this potentially allows cancer interventions to happen earlier and improves patient outcomes. “[Flamingo] will accelerate our efforts to realize a paradigm shift in cancer detection,” shares RenovaroCube CTO Frank van Asch. “With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 07, 2024 08:25 AM Eastern Daylight Time

Image

American Aires Inc. Executing a Strategy To Increase Exposure And Drive Sales

AAIRF, EDR, FOX, RUM

In our modern, technologically driven world, the proliferation of electronic devices emitting electromagnetic fields (EMFs) has raised significant concerns. While these EMFs have undoubtedly improved our lives in terms of convenience and connectivity, they also pose unintended health consequences. Scientific studies have shown that EMF radiation exposure can lead to brain inflammation, tissue damage, and the development of various diseases, including neurodegenerative conditions. This correlation between brain electrical activity and cognitive function underscores the potential risks of prolonged EMF exposure. Pioneering Protection Canadian-based nanotechnology company American Aires Inc. (CSE: WIFI) (OTC: AAIRF) has emerged as a pioneer in addressing the harmful effects of EMF radiation. With over 20 years of dedication and at least $20 million invested in research and development, American Aires has developed cutting-edge solutions to mitigate EMF exposure and optimize human health. The cornerstone of American Aires' technology is its proprietary silicon-based resonator, designed to protect against EMF radiation. Unlike traditional methods that aim to block or absorb radiation, American Aires' technology actively modulates EMFs, creating a protective barrier around electronic devices. These sleek and stylish devices provide personal and area protection without the need for a power source, targeting EMR emitted by various consumer electronic devices, including cellphones, computers, baby monitors, and Wi-Fi, including high-speed 5G networks. Scientific Validation The effectiveness of American Aires' microchip in reducing the harmful effects of EMF radiation has been reaffirmed by the scientific community. A recently published study in the Link Journal confirmed the chip's stabilizing capabilities, supported by eight peer-reviewed studies and 25 clinical and scientific reports, validating the technology. This scientific validation underscores the credibility and reliability of American Aires' solutions in the EMF protection space. Recent Exposure American Aires Inc. (OTC: AAIRF) (CSE: WIFI) American Aires has effectively prioritized public education and brand exposure, recognizing the pivotal role they play in expanding its market presence. CEO Josh Bruni's recent appearance on the Fox News Buiness Channel national TV series "Health Uncensored with Dr. Drew" on May 5, 2024, signifies a significant milestone for the company. This appearance provided a substantial platform for American Aires to showcase its innovative solutions to a vast audience. Broadcasting on a reputable network like Fox News (NASDAQ: FOX), which reaches hundreds of millions of households across the nation, underscores the magnitude of this opportunity. By featuring on such a prominent platform, AAIRF aimed to not only educate viewers about the importance of safeguarding against electromagnetic radiation but also to significantly raise awareness about the company and its mission. CEO Josh Bruni's presence on the program further solidified the company's commitment to transparency, education, and promoting awareness of its groundbreaking technology. To watch the segment and learn more about American Aires' innovative solutions, click here. Additionally, AAIRF has expanded its reach through a series of impactful partnerships and alliances. In a recent collaboration with Endeavor Group Holdings (NYSE: EDR ) subsidiary William Morris Endeavor Entertainment (WME), a powerhouse in the entertainment, sports, and fashion industries, American Aires aims to amplify its brand presence and extend its reach. This partnership promises to spotlight the manifold benefits of Aires' wellness and performance optimization solutions, leveraging WME's extensive network of top-tier artists, athletes, and content creators. The company's #airesathletes campaign further demonstrates its commitment to widening and deepening relationships with top athletes and celebrities. Partnering with renowned figures like Tiki Barber, the former NFL running back, American Aires showcases how its technology benefits athletes and consumers alike, promoting optimal performance and rapid recovery. Continuing its trajectory of strategic exposure, AAIRF announced a pivotal collaboration with Rumble Inc. (NASDAQ: RUM), a leading social video platform with a global reach. This partnership builds upon the company's ongoing efforts to amplify its brand presence and reach a wider audience. The groundwork for the Rumble partnership began over the past year, with AAIRF and RUM working together to test the traffic and conversion performance of the video platform. This collaboration paved the way for American Aires to officially launch a pilot test consisting of a paid ad campaign on Rumble. As part of this campaign, one of Rumble's most popular influencers, English comedian, actor, and influencer Russell Brand, with 1.87 million followers on the platform, will read one Aires ad per week over multiple episodes of his show on Rumble. Additionally, Rumble will display pre-roll "run of network" ad placements before or after Brand's shows air during the campaign. Commenting on the significance of this collaboration, American Aires CEO Josh Bruni stated, "It's very significant that this test campaign features Russell Brand. He not only aligns well with the Aires brand but also has a growing global audience through Rumble and across other media platforms that can reach potential Aires customers around the world." Financial Performance American Aires Inc. (OTC: AAIRF) has experienced robust revenue growth, doubling its revenue consistently over the past two years. In the first nine months of 2022 alone, the company generated $5.5 million in revenue, representing a 63% year-over-year increase. With extrapolated growth, American Aires could potentially achieve $10 million in sales in 2023. Moreover, AAIRF boasts superior profit margins, with gross margins averaging about 60%, rivaling top technology companies like Nvidia and Apple. The company reached a significant milestone by achieving positive adjusted EBITDA in its most recent quarter, highlighting its financial strength and growth potential. Furthermore, American Aires continues to demonstrate its industry leadership with recent announcements. The company achieved record Q4 and annual 2023 order volume, coupled with significant EBITDA profitability in Q4. This financial success reflects American Aires' sustained growth trajectory and its commitment to delivering value to shareholders. American Aires Inc. (OTC: AAIRF) (CSE: WIFI) stands at the forefront of the EMF protection and human optimization industries, offering innovative solutions to address the growing concerns surrounding electromagnetic radiation. Recent advancements, strong financial results, partnerships, and scientific validation of its patented technology all contribute to American Aires reaffirming its leadership in enhancing human well-being in a technology-driven world. As the company continues to innovate and expand its reach, it remains a stock to watch for any smart investor. For more information https://airestech.com/ Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained by Clarkham Capital International to assist in the production and distribution of content related to AAIRF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://RazorPitch.com

May 07, 2024 07:00 AM Eastern Daylight Time

Image